Ademi LLP is investigating AlloVir (Nasdaq: ALVR) for possible breaches of fiduciary duty and other violations of law in its transaction with Kalaris.
In the transaction, stockholders of AlloVir will own only approximately 25.05% of the combined company and pre-Merger Kalaris stockholders are expected to own approximately 74.95% of the combined company. The transaction agreement unreasonably limits competing transactions for AlloVir by imposing a significant penalty if AlloVir accepts a competing bid. AlloVir insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of AlloVir’s board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.